IP Library Granted Patent US 9,056,106
Granted Patent B2
US 9,056,106 · App. 12/836,536 · Granted Jun 16, 2015

Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,056,106
App. No.
12/836,536
Granted
Jun 16, 2015
Kind
B2
Abstract

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Claims (8)

1. A unit dose formulation consisting essentially of a pharmaceutically acceptable carrier and from about 200 milligrams to about 1 gram of a two-chain polypeptide comprising the amino acid sequence of SEQ ID NO. 13.

2. The unit dose formulation of claim 1 , having from about 400 milligrams to about 900 milligrams of the polypeptide.

3. The unit dose formulation of claim 1 , wherein the carrier is saline.

4. The unit dose formulation of claim 3 , wherein the formulation has a concentration of from about 0.2 to about 10 milligrams of polypeptide per milliliter of saline.

5. The unit dose formulation of claim 4 , wherein the formulation has a concentration of about 2 to about 6 milligrams of polypeptide per milliliter of saline.

6. The unit dose formulation of claim 5 , wherein the formulation has a concentration of about 2 milligrams of polypeptide per milliliter of saline.

7. The unit dose formulation of claim 1 , wherein the polypeptide is lyophilized.

8. The unit dose formulation of claim 1 , having about 200, about 400 or about 900 milligrams of the polypeptide.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2022
From: ALEXION PHARMACEUTICALS, INC.
To: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
Reel/Frame 060799/0729 →
CHANGE OF NAME Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054920/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054921/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054922/0857 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
SECURITY INTEREST Recorded Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2010
From: SINHA, UMA; LU, GENMIN; HUTCHALEELAHA, ATHIWAT; HOLLENBACH, STANLEY J.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 025024/0354 →